<DOC>
	<DOCNO>NCT00116740</DOCNO>
	<brief_summary>This research study investigational drug , APD356 , novel , selective 5-HT2c receptor agonist , clinical development potential treatment obesity . The purpose study obtain preliminary assessment safety efficacy APD356 , administer daily 12 week , obese subject otherwise healthy . Subjects concomitant medication control hypertension blood lipid may qualify .</brief_summary>
	<brief_title>Safety Efficacy APD356 Treatment Obesity</brief_title>
	<detailed_description>This double-blind , placebo-controlled , randomize , parallel group study . Three different dos APD356 placebo administer daily 12 week , obese , male nonpregnant , nonlactating , female volunteer , age 18 65 year . Approximately 400 subject enrol .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<criteria>Healthy male nonpregnant , nonlactating female age 1865 year ( inclusive ) Body mass index ( BMI ) 3045 kg/m2 Nonsmoker No concomitant medication hypertension medication ( stable &gt; 90 day ) and/or statin ( stable &gt; 90 day ) No past treatment drug associate development pulmonary hypertension cardiac valvular insufficiency No mild mitral valve regurgitation absence aortic valve regurgitation upon screen echocardiogram</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>Serotonin</keyword>
	<keyword>5-HT2c</keyword>
	<keyword>Satiety</keyword>
	<keyword>Obesity</keyword>
	<keyword>Appetite suppressant</keyword>
	<keyword>Weight Loss</keyword>
	<keyword>Overweight</keyword>
</DOC>